Loading patent…
AssigneeNational University Corporation Okayama University
InventorsMasakiyo SAKAGUCHI, Shinichi TOYOOKA, Rie KINOSHITA, Kota ARAKI
Estimating the term…
The present invention provides an inflammatory pulmonary disease agent capable of effectively preventing and/or treating an inflammatory pulmonary disease, and specifically relates to a prophylactic and/or therapeutic agent for an inflammatory pulmonary disease containing, as an active ingredient, an antibody or an antibody fragment having antigen-binding activity for an S100A8/A9 heterodimer. The inflammatory pulmonary disease can be effectively prevented and/or treated by blocking interaction between S100A8/A9 and a group of receptors therefor. Specifically, the inflammatory pulmonary disease can be effectively prevented and/or treated by: blocking interaction between S100A8/A9 and RAGE, which is a receptor therefor, to suppress: the expression of NF-κB, which is a transcription factor present downstream of RAGE and induces the expression of various inflammatory cytokines; the proliferation of activated fibroblasts; and the differentiation of activated fibroblasts into myofibroblasts. In addition, the prophylactic and/or therapeutic agent for an inflammatory pulmonary disease of the present invention may also be suitably used as a prophylactic and/or therapeutic agent for COVID-19.
1-14. (canceled)
A prophylactic and/or therapeutic agent for an inflammatory pulmonary disease, comprising an antibody or an antibody fragment as an active ingredient, the antibody or the antibody fragment having antigen-binding activity for a heterodimer of an S100A8 protein and an S100A9 protein, the antibody or the antibody fragment having antigen-binding activity for the heterodimer of the S100A8 protein and the S100A9 protein higher than antigen-binding activity for each of an S100A8 monomer and an S100A9 monomer.
A prophylactic and/or therapeutic method for an inflammatory pulmonary disease, said method comprising utilizing an antibody or an antibody fragment as an active ingredient, the antibody or the antibody fragment having antigen-binding activity for a heterodimer of an S100A8 protein and an S100A9 protein, the antibody or the antibody fragment having antigen-binding activity for the heterodimer of the S100A8 protein and the S100A9 protein higher than antigen-binding activity for each of an S100A8 monomer and an S100A9 monomer.
Dependencies are inferred from the claim text.